Great news. I'm glad IMUC management keeps shareholders and the rest of the public, up to date on trial progress. I have owned too many other companies that kept me in the dark. This is terrific news as they are enrolling at a such a fast pace.
Big pharma is watching this trial closely, if interim data is anywhere close to that of the phase 1 trial, IMUC will be the topic of buy out from several major drug makers.